Moderna and Merck released full phase three data on October 22, 2026 for their personalized mRNA cancer vaccine, intismeran, in melanoma. Combined with Keytruda, it cut the risk of recurrence or death by 42% over two years and distant spread or death by 38% versus Keytruda alone, with a 33% decline in death. Coverage splits on whether 42% clears investor expectations. The discussion has since moved to what comes next: a kidney cancer readout is expected at the end of the year or early next year, with lung cancer framed as the big test.